Objective-To determine the relation between maternal serum cx fetoprotein and free 1 human chorionic gonadotrophin concentrations in pregnancies complicated by trisomy 18 
Introduction
Biochemical screening for trisomy 21 can now identify 65-75% of cases early in the second trimester, particularly when combinations of a fetoprotein and free 1 human chorionic gonadotrophin concentrations are used as markers. 1-6The prospect of first trimester screening with these analytes to achieve detection rates exceeding 50% seems a definite possibility.7-9 The impetus for all this development was the finding by one of us of a low matemal serum ot fetoprotein concentration in a case of trisomy 18.10 Trisomy 18 is the second most frequent autosomal trisomy (after trisomy 21) and has a birth incidence of between one in 7000 and one in 8000.1 As in the case of trisomy 21, the birth incidence increases with matemal age.'"-13 The condition is associated with multiple malformations and livebom infants rarely survive beyond the first year." Around 70% of affected pregnancies end in spontaneous abortion in the third trimester and extreme growth retardation is common." An open neural tube defect or ventral wall defect occurs in a quarter of cases. '4 The low matemal serum cx fetoprotein concentr6-tions in cases of trisomy 18 uncomplicated by neural tube defect or ventral wall defect have been confirmed by several groups.""'6 Investigating other analytes for use in trisomy 21 screening, other workers have found reduced concentrations of unconjugated oestriol in pregnancies affected by trisomy 18.15 1718 Matemal serum intact of total human chorionic gonadotrophin concentrations are also lower in pregnancies affected by trisomy 18,5 1920 22 We examined the two markers used in our trisomy 21 and neural tube defect screening programmesnamely, cx fetoprotein and free 1 human chorionic gonadotrophin-to see whether they might be used to screen for trisomy 18 also.
Subjects and methods
The trisomy 18 population comprised women who presented through the neural tube defect and Down's syndrome screening programmes in our 
Results
The median serum free ( human chorionic gonadotrophin value in the trisomy 18 pregnancies was 0 37 multiple of the median (95% confidence interval 0-27 to 0A42), with a range of 0-02-1-83. The median value was significantly lower (p<0-001) than in unaffected pregnancies.
The median serum cx fetoprotein value in the trisomy 18 pregnancies was 0-71 multiple of the median (0-62 to 0-81), with a range of 0-19-1M41. The median value was significantly lower (p<0-001) than in unaffected pregnancies. Figure 1 shows the individual oa fetoprotein and free a human chorionic gonadotrophin concentrations plotted as multiples of the median value for each case associated with trisomy 18. with the analyte concentration in a univariate risk calculation and the likelihood ratios then used in the population model significant improvements in detection rates were observed. When the two analytical measurements were combined bivariately with the a priori age related risk at a 1% false positive rate a detection rate of 50% was predicted (equivalent to a trisomy 18 risk of one in 250 or greater).
Discussion
The median value of 0-71 for serum cx fetoprotein concentration in our series of 52 trisomy 18 cases is consistent with other reports,' 22 and the median value of 0-37 for free 3 human chorionic gonadotrophin concentration is in good agreement with that reported by Staples et aP22 in their study of 12 cases of trisomy 18 using an assay with 0 4% cross reactivity with intact human chorionic gonadotrophin. Our median free 3 human chorionic gonadotrophin value is also close to that observed by us in a series in the first trimester. 7 Canick et al proposed a screening protocol for trisomy 18 based on the use of three markers (ot fetoprotein, total human chorionic gonadotrophin, and unconjugated oestriol) and specified multiple of the median cut off values which could be expected to identify 60% of trisomy 18 cases uncomplicated by neural tube defect or ventral wall defect with a 0 4% false positive rate.'5 Palomaki et al recently reported using the protocol in a prospective screening pro- 28 gramme. In their population of 19491 women they predicted from published incidence figures and figures for fetal loss in the third trimester that seven cases of trisomy 18 should be observed in the second trimester. From their screening programme they identified six cases and hence suggested an 85% detection rate. The false positive rate was 0-5%.28 This method of "ascertainment" of the number of affected cases in a screening population is only an approximation and may lead to considerable error in estimating detection rates. 6 Staples et al proposed a screening protocol for trisomy 18 based on using five biochemical markersfree I human chorionic gonadotrophin, free ot human chorionic gonadotrophin, unconjugated oestriol, oestradiol, and human placental lact9gen.22 From their study of 12 cases they predicted a 75% detection rate for a 1% false positive rate. With the five analytes that they used in their trisomy 21 screening programme, they predicted a 72% detection rate for trisomy 18. All these studies and simulations were based on small numbers of trisomy 18 cases, so that the confidence intervals for detection rates were very wide.
Greenberg et aP' recently applied the screening criteria of Canick et aP5 to a study of trisomy 18 cases. Although the median values they observed were close to those described by Canick et al," the detection rate was only 29%. A significant difference between the two studies lay in the distribution of total human chorionic gonadotrophin values. Canick et al showed that the 5th centile of the unaffected population was 045 multiple of the median,'5 but Greenberg et al found 0 45 to be closer to the 10th centile." Other studies of total human chorionic gonadotrophin have also shown that this equates more closely to the 10th centile.42' Our distribution of free 0 human chorionic gonadotrophin values also suggests that 0 45 multiple of the median is very close to the 10th centile.
Clearly the human chorionic gonadotrophin concentration distribution observed by Canick et al is atypical.
The study by Greenberg et at" also shows that the total human chorionic gonadotrophin distribution observed in the affected population is considerably wider than in the few cases described by Canick et al. '5 Similarly our study of a much larger affected population suggests Clinical implications * Biochemical screening programmes using a fetoprotein and free ,B human chorionic gonadotrophin have been shown prospectively to detect 70% oftrisomy 21 cases * Trisomy 18 is the second most common autosomal trisomy with a birth incidence of 1 in 7000 * Concentrations of maternal serum a fetoprotein and free , human chorionic gonadotrophin are lower than normal in trisomy 18 affected pregnancies * The use of maternal age and the concentrations of the two serum markers makes it possible to identify at least half of trisomy 18 cases with a false positive rate of only 1% * Biochemical screening and patient specific risk reporting for trisomy 18 should become an additional part of existing trisomy 21 screening programmes that the distribution of free I human chorionic gonadotrophin concentrations is wider than that observed by Staples et al. 22 Our study represents the largest single collection of trisomy 18 cases reported. Consequently the confidence intervals associated with our estimates are considerably tighter than those in other studies. Using our standard trisomy 21 screening assay protocol, but calculating specific trisomy 18 risk, we estimate that of the trisomy cases not compromised by neural tube defect or ventral wall defect, our protocol will detect 50% (95% confidence interval 35-8 to 64 2) for a 1% false positive rate (0 75 to 1-23). However, by using a combination of raised a fetoprotein concentrations found in the quarter of cases with neural tube defect or ventral wall defect and the proposed new protocol (which detects 50% of the remaining 75%) 60-65% of all trisomy 18 cases could be identified. We find these data sufficiently encouraging to suggest that trisomy 18 risk algorithms should be introduced into routine Down's syndrome screening programmes and further prospective evaluations should be carried out. 
Introduction
Much research into social inequalities in health has concentrated on deprived urban areas and little is known about patterns of health in rural areas.'-3. Although poverty and deprivation are less visible in rural areas, there are wide variations in the social conditions in which people live.45 that are likely to be reflected in inequalities in health. There is conflicting evidence that health may be better in rural areas,3'67 but much of this is extrapolated from mortality data. Whether urban living itself compromises health over and above socioeconomic disadvantage or whether the poorer health in urban areas simply reflects greater deprivation is not known.
In order to move the focus of evidence away from mortality data birth weight and children's height may be used as measures of health. These vary with social circumstances8-" and reflect important aspects of past, present, and future health potential of children.8 1012 13
Studies comparing rural and urban pattems of height and birth weight while controlling for socioeconomic differences have had inconclusive results. The national study of health and growth found that children were taller in rural areas and suggested that this was due to unmeasured socioeconomic differences. '4 In the north of England3 rates of low birth weight were lower in remote rural areas than in comparable urban areas, although not in rural areas which were nearer to the centres of population.
This study looks more closely into rural and urban differences in birth weight and height by using data collected for a study measuring links between child health and material deprivation in the county of Northumberland, in the north of England. There are six local authority districts within Northumberland (see fig 1) . Four are predominantly rural, with low population densities, large tracts of coastal and hill country, and numerous small rural towns. The two more urban districts are in the south east of the county (Blyth Valley and Wansbeck). Wide social disparities exist in all these settings, and these have been demonstrated by using small area methods, census enumeration districts being classified by the Townsend material deprivation index.'5 This enables rates of low birth weight and mean heights of primary school children to be compared between enumeration districts at equivalent levels of deprivation in different rural and urban settings.
Population and methods
Collection of the child health data has been described. '6 Briefly, data on birth weight were taken from the district child health information system on a
